WuXi NextCODE gets 100,000 Genomes contract

The WuXi NextCODE subsidiary of WuXi PharmaTech Inc. (NYSE:WX) entered a contract with Genomics England Ltd. (London, U.K.) to interpret genomic data from patients participating in the U.K.'s 100,000 Genomes Project. The project aims to sequence and study the genomes of 100,000 NHS England patients by 2017, with a focus on rare diseases and cancer.

NHS clinicians will use WuXi NextCODE's sequence analysis platform to identify causative variants in rare diseases and driver mutations in cancer. WuXi NextCODE COO Hannes Smarason declined to disclose financial terms of the deal. ...